Beijing Tong Ren Tang secures Canadian product license for traditional medicine

Beijing Tong Ren Tang Co., Ltd. announced that its subsidiary, Beijing Tong Ren Tang Pharmaceuticals, has received a Class III Product License from Health Canada for its product, Shen Ling Bai Zhu San. This license allows for the sale of this traditional Chinese medicine in Canada.

Shen Ling Bai Zhu San is described as a traditional Chinese medicine used to alleviate symptoms of spleen and stomach weakness, including reduced appetite, loose stools, shortness of breath, cough, and general fatigue. The product is a powder and has been assigned approval number 80143529. As of the announcement date, the research and development investment for this product totaled approximately CNY 2.29 million.

While this approval marks a significant step, the company noted that further regulatory steps are required for commercial sales in Canada, including facility certification under Canadian Good Manufacturing Practices. These subsequent approvals introduce a degree of uncertainty. The company emphasized that this development is not expected to significantly impact its near-term operating performance and urged investors to exercise caution due to potential market, policy, and competitive risks in overseas sales.